Liquidia (NASDAQ:LQDA) CFO Michael Kaseta Sells 36,932 Shares

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 36,932 shares of Liquidia stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,382,364.76. Following the completion of the sale, the chief financial officer owned 350,919 shares of the company’s stock, valued at approximately $13,134,898.17. The trade was a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 1st, Michael Kaseta sold 1,166 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total value of $37,533.54.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $38.09 on Wednesday. The business has a fifty day moving average price of $32.14 and a two-hundred day moving average price of $25.58. The stock has a market capitalization of $3.31 billion, a PE ratio of -26.45, a P/E/G ratio of 1.22 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $39.29.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. The company’s revenue was up 1106.7% compared to the same quarter last year. As a group, equities analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently bought and sold shares of LQDA. Whitcomb & Hess Inc. raised its position in Liquidia by 2.0% in the third quarter. Whitcomb & Hess Inc. now owns 28,385 shares of the company’s stock valued at $645,000 after purchasing an additional 558 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Liquidia by 1.4% in the third quarter. Alliancebernstein L.P. now owns 67,050 shares of the company’s stock valued at $1,525,000 after buying an additional 900 shares during the period. Ballentine Partners LLC raised its holdings in Liquidia by 10.2% in the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock valued at $151,000 after buying an additional 1,119 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in Liquidia by 24.0% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after buying an additional 1,200 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ acquired a new stake in Liquidia during the 3rd quarter worth approximately $30,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined about 18.1% to ~10.71M shares as of Dec. 31 (about 17.6% of shares outstanding), lowering potential downward pressure from short sellers and reducing immediate squeeze risk.
• Neutral Sentiment: Reported short-interest data for Jan. 12 appears inconsistent (shows 0 shares / NaN change), which looks like a reporting glitch and should be treated as unreliable until corrected.
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average of $37.43 for roughly $2.49M, reducing his direct stake by ~6.0%. SEC Filing – Roger Jeffs
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 for about $1.38M, a ~9.5% reduction in his holding. SEC Filing – Michael Kaseta
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 for about $1.02M, a ~4.5% stake reduction. SEC Filing – Russell Schundler
• Negative Sentiment: Insider Rajeev Saggar sold 21,142 shares at $37.43 (~$791k), cutting his holdings by ~10.7%. SEC Filing – Rajeev Saggar
• Negative Sentiment: Scott Moomaw sold 20,533 shares at $37.43 (~$769k), an ~11.7% reduction in his stake. SEC Filing – Scott Moomaw
• Negative Sentiment: CAO Dana Boyle sold 11,047 shares at $37.43 (~$413k), a ~6.6% reduction. SEC Filing – Dana Boyle
• Negative Sentiment: Insider Jason Adair sold 13,548 shares at $37.43 (~$507k), and Sarah Krepp sold 13,165 shares (~$493k); both reduced holdings by mid-single-digit to high-single-digit percentages. SEC Filing – Jason Adair SEC Filing – Sarah Krepp

Wall Street Analyst Weigh In

Several research firms recently issued reports on LQDA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. Needham & Company LLC lifted their price target on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Jefferies Financial Group boosted their price target on Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday. Wall Street Zen raised Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, HC Wainwright lifted their target price on Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).